FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

📅 18/06/2026 05:00 📰 eagletribune 👁️ 4 lectures 🌍 États-Unis 📂 Santé

$FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma$

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 18, 2026--